Robert M. Rifkin - Concepedia

Author

Robert M. Rifkin

Also Known As

R M Rifkin, R Rifkin, R. M. Rifkin, R. Rifkin, R.M. Rifkin, Rifkin R. M., Robert M Rifkin, Robert M. Rifkin, Robert Rifkin, The MMRF CoMMpass Network

257

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Rocky Mountain Cancer Centers Indiana University – Purdue University Indianapolis Sarah Cannon The University of Texas MD Anderson Cancer Center Millennium Engineering and Integration (United States)

About

Robert M. Rifkin is an author at Rocky Mountain Cancer Centers specializing in medicine, oncology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1.4K
2	Health Sciences	11	12	931
3	Engineering	1	1	24
4	Natural Sciences	1	1	41
5	Public Health	1	1	33

Robert M. Rifkin

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Shaji Kumar, Ian W. Flinn, Paul G. Richardson, Blood	2012	449
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, The Lancet Haematology Hematological MalignancyMedicineImmunologyClinical TrialsHematology	2019	237
High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study Raymond B. Weiss, Robert M. Rifkin, F. Marc Stewart, The Lancet Breast OncologyOncologyBezwoda StudyBreast CancerHigh-dose Chemotherapy	2000	163
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens Rubén Niesvizky, Ian W. Flinn, Robert M. Rifkin, Journal of Clinical Oncology	2015	151
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma Robert M. Rifkin, Stephanie A. Gregory, Ann Mohrbacher, Cancer	2006	131
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma Vânia Hungria, Paweł Robak, Marek Hus, New England Journal of Medicine	2024	127
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma Michael Crump, Sirpa Leppä, Luis Fayad, Journal of Clinical Oncology	2016	122
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial Rami S. Komrokji, Guillermo Garcia‐Manero, Lionel Adès, The Lancet Haematology Hematological MalignancyBone Marrow FailureHematologyClinical TrialsMyeloid Neoplasia	2018	118
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma Mohamad A. Hussein, Mansoor N. Saleh, Farhad Ravandi, British Journal of Haematology ImmunologyPathologyCell DeathMetronomic ChemotherapyImmunotherapy	2004	115
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma James R. Berenson, Alan Cartmell, Alberto Bessudo, Blood	2016	94

Page 1